Core Viewpoint - EverQuote (EVER) shares have shown a modest gain of 0.4% over the past four weeks, closing at $22.41, with analysts suggesting a potential upside of 48% based on a mean price target of $33.17 [1] Price Targets and Analyst Consensus - The average price target for EVER is based on six short-term estimates, ranging from a low of $29.00 to a high of $38.00, with a standard deviation of $3.43, indicating a potential increase of 29.4% to 69.6% from the current price [2] - A low standard deviation suggests strong agreement among analysts regarding the price movement of EVER, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about EVER's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [11] - Over the last 30 days, one earnings estimate has increased, leading to a 0.1% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - EVER holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13] - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Core Insights - Analysts project that Sunrun (RUN) will report quarterly earnings of $0.01 per share, reflecting a year-over-year increase of 102.7% [1] - Revenue is expected to reach $604.92 million, marking a 12.6% increase from the same quarter last year [1] Earnings Estimates Revisions - The consensus EPS estimate has been revised upward by 1204.1% over the past 30 days, indicating a significant reassessment by analysts [2] - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock [3] Revenue Projections - Analysts estimate 'Revenue- Customer agreements and incentives' at $474.30 million, a year-over-year change of +16.9% [5] - 'Revenue- Solar energy systems and product sales' is projected to reach $124.98 million, reflecting a decrease of -4.8% from the previous year [5] - 'Revenue- Solar energy systems' is expected to be $60.78 million, indicating a year-over-year increase of +28.8% [6] - 'Revenue- Incentives' is projected at $46.77 million, showing a year-over-year increase of +25.6% [6] - 'Revenue- Products' is estimated to be $68.49 million, reflecting a decrease of -18.6% from the previous year [6] - 'Revenue- Customer agreements' is expected to reach $467.67 million, a year-over-year increase of +26.9% [7] Profit and Cost Estimates - 'Gross Profit- Solar Energy Systems and Product' is projected at $10.03 million, up from $6.00 million in the same quarter last year [7] - 'Gross Profit- Customer Agreements and Incentives' is expected to be $109.96 million, compared to $97.48 million a year ago [8] - 'Cost of solar energy systems and product sale' is estimated at $114.95 million [8] - The consensus estimate for 'Cost of customer agreements and incentives' stands at $375.04 million [8] Stock Performance - Over the past month, Sunrun shares have returned +3.7%, outperforming the Zacks S&P 500 composite's +2.1% change [8] - Sunrun currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [8]

Wall Street analysts expect Teva Pharmaceutical Industries Ltd. (TEVA) to post quarterly earnings of $0.68 per share in its upcoming report, which indicates a year-over-year decline of 1.5%. Revenues are expected to be $4.35 billion, up 0.4% from the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the c ...

Wall Street analysts expect Dutch Bros (BROS) to post quarterly earnings of $0.17 per share in its upcoming report, which indicates a year-over-year increase of 6.3%. Revenues are expected to be $411.13 million, up 21.6% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 2.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings a ...

Core Insights - Analysts expect Qualcomm (QCOM) to report quarterly earnings of $2.87 per share, reflecting a year-over-year increase of 6.7% and revenues of $10.77 billion, up 5.2% from the previous year [1] Earnings Estimates - There has been a slight downward revision of 0.1% in the consensus EPS estimate over the last 30 days, indicating a reconsideration of forecasts by analysts [1][2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [2] Revenue Projections - Analysts estimate 'Revenues- QTL' at $1.40 billion, a decrease of 7.9% year-over-year [4] - 'Revenues- QCT- Automotive' is forecasted to reach $1.02 billion, indicating a year-over-year increase of 13.8% [4] - 'Revenues- QCT- IoT' is expected to be $1.70 billion, reflecting a slight increase of 0.8% year-over-year [4] - 'Revenues- QCT- Handsets' is projected at $6.56 billion, showing a year-over-year increase of 7.6% [5] - The consensus for 'Revenues- QCT' is $9.28 billion, indicating a year-over-year change of 6.9% [5] - 'Revenues- Licensing' is expected to be $1.50 billion, reflecting a decrease of 12.4% year-over-year [5] - 'Revenues- Equipment and services' is projected at $9.16 billion, indicating a year-over-year increase of 7.3% [6] Income Estimates - 'Income / (loss) before taxes- QTL' is expected to reach $975.60 million, down from $1.12 billion reported in the same quarter last year [6] - 'Income / (loss) before taxes- QCT' is projected at $2.66 billion, compared to $2.47 billion reported in the same quarter last year [7] Stock Performance - Qualcomm shares have increased by 5% over the past month, outperforming the Zacks S&P 500 composite, which moved up by 2.1% [7]

Core Insights - Analysts project that Cava Group (CAVA) will report quarterly earnings of $0.13 per share, reflecting a year-over-year decline of 13.3% while revenues are expected to reach $293.31 million, marking a 20.3% increase from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised downward by 18% in the past 30 days, indicating a reassessment by covering analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock price performance [3] Revenue and Sales Growth - Analysts estimate that 'Revenue- CAVA Restaurant' will reach $292.18 million, representing a year-over-year change of +21% [4] - The average prediction for 'CAVA Same Restaurant Sales Growth' is 3.2%, a significant decrease from the previous year's figure of 18.1% [5] Restaurant Metrics - The estimated number of 'End of period CAVA Restaurants' is 416, up from 352 year-over-year [5] - Analysts project 17 new CAVA restaurant openings, including converted Zoes Kitchen locations, compared to 11 in the previous year [5] Profitability and Occupancy - 'Occupancy as a percentage of CAVA Revenue' is expected to be 6.7%, slightly down from 6.8% in the same quarter last year [6] - 'Restaurant-Level profit- CAVA' is estimated to reach $73.71 million, an increase from $61.82 million year-over-year [6] Stock Performance - Cava shares have decreased by 2% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3.6% [6] - CAVA holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market in the near term [6]

Core Insights - Analysts project Amgen (AMGN) will report quarterly earnings of $5.00 per share, reflecting a 10.4% decline year over year, with revenues expected to reach $8.94 billion, a 5.2% increase from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been adjusted downward by 0.9% over the past 30 days, indicating a reassessment by covering analysts [1][2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [2] Revenue Projections - Analysts estimate 'Revenue- Other revenues' at $373.34 million, indicating a year-over-year change of +6.1% [4] - 'Revenue- Product sales' is projected to be $8.55 billion, reflecting a +4.8% change from the prior-year quarter [4] Product Sales Forecasts - 'Product Sales- BLINCYTO- Total' is expected to reach $412.70 million, showing a +26.2% change year over year [4] - 'Product Sales- Otezla- Total' is forecasted at $582.08 million, indicating a +3.2% change [5] - 'Product Sales- Neulasta- U.S.' is expected to be $60.90 million, reflecting a -27.5% change [5] - 'Product Sales- Repatha- U.S.' is projected at $367.86 million, indicating a +30.9% change [6] - 'Product Sales- BLINCYTO- U.S.' is expected to reach $298.45 million, reflecting a +25.9% change [7] Market Performance - Amgen shares have shown a return of -2.3% over the past month, compared to a +3.6% change in the Zacks S&P 500 composite [8]

Core Insights - Farmland Partners (FPI) reported quarterly funds from operations (FFO) of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and up from $0.03 per share a year ago [1][2] - The company achieved an FFO surprise of +16.67% this quarter, having previously missed estimates by -25% in the prior quarter [2] - Revenues for the quarter ended September 2025 were $11.25 million, surpassing the Zacks Consensus Estimate by 5.64%, but down from $13.32 million year-over-year [3] Financial Performance - Over the last four quarters, Farmland Partners has surpassed consensus FFO estimates two times and revenue estimates three times [2][3] - The current consensus FFO estimate for the upcoming quarter is $0.17 on revenues of $16.92 million, and for the current fiscal year, it is $0.30 on revenues of $47.78 million [8] Market Position - Farmland Partners shares have declined approximately 12.5% year-to-date, contrasting with the S&P 500's gain of 17.2% [4] - The Zacks Industry Rank places the REIT and Equity Trust - Other sector in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [9] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future FFO expectations [4] - The estimate revisions trend for Farmland Partners was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market [7]

Core Insights - Rocket Companies (RKT) is expected to report quarterly earnings of $0.04 per share, reflecting a year-over-year decline of 50% [1] - Revenue is anticipated to reach $1.75 billion, showing an increase of 32.1% compared to the same quarter last year [1] Earnings Estimates Revisions - The consensus EPS estimate has been revised 37.5% higher over the last 30 days, indicating a collective reevaluation by analysts [2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [3] Revenue Projections - Analysts project 'Revenue- Gain on sale of loans- Gain on sale of loans excluding fair value of MSRs, net' to be $547.46 million, a year-over-year change of +8.1% [5] - 'Revenue- Gain on sale of loans- Fair value of originated MSRs' is estimated at $376.96 million, reflecting an increase of +11.6% from the prior year [5] - 'Revenue- Loan servicing income- Servicing fee income' is projected at $406.53 million, indicating a year-over-year change of +8.8% [6] - 'Revenue- Other income' is expected to be $446.97 million, showing a significant year-over-year change of +48.8% [6] - 'Revenue- Gain on sale of loans, net' is projected to reach $924.41 million, a change of +9.5% from the year-ago quarter [7] - 'Revenue- Interest income, net' is expected at $34.34 million, indicating a substantial change of +409% from the prior year [7] - 'Revenue- Interest income- Interest income' is projected to be $114.19 million, reflecting a year-over-year change of +5.2% [7] Stock Performance - Over the past month, shares of Rocket Companies have returned -9.7%, contrasting with the Zacks S&P 500 composite's +3.8% change [8] - Currently, RKT holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [8]

Core Insights - Analysts project Insmed (INSM) will report a quarterly loss of -$1.32 per share, a decline of 3.9% year over year, with revenues expected to reach $114.65 million, an increase of 22.7% from the same quarter last year [1] Earnings Projections - The consensus EPS estimate for the quarter has been revised downward by 0.6% over the past 30 days, indicating a collective reassessment by analysts [2] - Revisions to earnings projections are crucial for predicting investor behavior, as empirical studies show a strong correlation between earnings estimate trends and short-term stock performance [3] Revenue Estimates - Analysts estimate 'Revenue- Japan' at $29.88 million, reflecting a year-over-year increase of 42.4% [5] - The 'Revenue- Europe and rest of world' is projected at $7.24 million, indicating a 29.8% year-over-year change [5] - 'Revenue- U.S.' is expected to reach $72.72 million, showing an 8.8% increase year over year [5] Stock Performance - Insmed shares have returned +14.8% over the past month, outperforming the Zacks S&P 500 composite, which saw a +3.8% change [5] - With a Zacks Rank 3 (Hold), Insmed is anticipated to reflect overall market performance in the near future [5]